Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
Physicians should encourage pharmaceutical companies to make socially responsible funding decisions and take an active role in setting biomedical research priorities by advocating for fair and effective allocations of public and private biomedical R & D investments.
A Canadian physician reports there is systematic bias to the outcome of published research funded by the pharmaceutical industry and believes more steps need to be taken to improve the integrity of clinical research reports in the United States and Canada.
While some argue that live footage of emergency room treatment is beneficial to the general public, the AMA's Code of Medical Ethics states that such taping is a violation of patient privacy and patient confidentiality.
Physicians are obligated to inform patients involved in a clinical trial that there is a chance of receiving a placebo, which can result in a deterioration of a medical condition.
Physicians are obligated to inform patients involved in a clinical trial that there is a chance of receiving a placebo, which can result in a deterioration of a medical condition.